Literature DB >> 10605732

Cyclic nucleotides and phosphodiesterases in platelets.

R J Haslam1, N T Dickinson, E K Jang.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10605732

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  25 in total

1.  Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice.

Authors:  Benoit Decouture; Elise Dreano; Tiphaine Belleville-Rolland; Orjeta Kuci; Blandine Dizier; Amine Bazaa; Bérard Coqueran; Anne-Marie Lompre; Cécile V Denis; Jean-Sébastien Hulot; Christilla Bachelot-Loza; Pascale Gaussem
Journal:  Blood       Date:  2015-08-27       Impact factor: 22.113

Review 2.  New Concepts and Mechanisms of Platelet Activation Signaling.

Authors:  Brian Estevez; Xiaoping Du
Journal:  Physiology (Bethesda)       Date:  2017-03

3.  Thrombin and collagen induce a feedback inhibitory signaling pathway in platelets involving dissociation of the catalytic subunit of protein kinase A from an NFkappaB-IkappaB complex.

Authors:  Stepan Gambaryan; Anna Kobsar; Natalia Rukoyatkina; Sabine Herterich; Joerg Geiger; Albert Smolenski; Suzanne M Lohmann; Ulrich Walter
Journal:  J Biol Chem       Date:  2010-03-31       Impact factor: 5.157

Review 4.  Anti-platelet therapy: phosphodiesterase inhibitors.

Authors:  Paolo Gresele; Stefania Momi; Emanuela Falcinelli
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

5.  Endogenous cGMP-dependent protein kinase reverses EGF-induced MAPK/ERK signal transduction through phosphorylation of VASP at Ser239.

Authors:  Yan Tao; Yin-Jie Gu; Zhi-Hong Cao; Xiu-Juan Bian; Ting Lan; Jian-Rong Sang; Lu Jiang; Ying Wang; Hai Qian; Yong-Chang Chen
Journal:  Oncol Lett       Date:  2012-08-06       Impact factor: 2.967

Review 6.  Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action.

Authors:  Osamu Yokoyama; Yasuhiko Igawa; Masayuki Takeda; Takafumi Yamaguchi; Masahiro Murakami; Lars Viktrup
Journal:  Ther Adv Urol       Date:  2015-10

Review 7.  Drug treatment of intermittent claudication.

Authors:  Douglas Jacoby; Emile R Mohler
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  Harnessing the platelet signaling network to produce an optimal hemostatic response.

Authors:  Lawrence F Brass; Maurizio Tomaiuolo; Timothy J Stalker
Journal:  Hematol Oncol Clin North Am       Date:  2013-04-11       Impact factor: 3.722

9.  Phosphodiesterase 3 is present in rabbit and human erythrocytes and its inhibition potentiates iloprost-induced increases in cAMP.

Authors:  Madelyn S Hanson; Alan H Stephenson; Elizabeth A Bowles; Meera Sridharan; Shaquria Adderley; Randy S Sprague
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-27       Impact factor: 4.733

Review 10.  Targeting phosphodiesterases in anti-platelet therapy.

Authors:  Matthew T Rondina; Andrew S Weyrich
Journal:  Handb Exp Pharmacol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.